Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-cell Acute Lymphoblastic Leukemia
Furun AnHuiping WangZhenyun LiuFan WuJiakui ZhangQianshan TaoYingwei LiYuanyuan ShenYanjie RuanQing ZhangYing PanWeiwei ZhuHui QinYongling FuYansheng WangZhenqing FengZhimin Zhai
0
Citation
0
Reference
10
Related Paper
Abstract:
This is the Source Data of the paper titled “Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-cell Acute Lymphoblastic Leukemia”.Although chimeric antigen receptor (CAR)-T therapy has produced remarkable clinical responses for patients with relapsed or refractory hematological malignancies, setbacks were experienced, including antigen escape and heterogeneity, its efficacy and safety issues. In recent years, researchers at home and abroad are addressing the current obstacles by digging deeply into structural optimization of CAR gene in order to solve the problems of CAR-T cell therapy. In this review, we mainly illustrate the ectodomain structure, transmemberane domain, and endodomain structure, and new designs which promote persistence of CAR-T cells in vivo, so as to provide new ideas for improving the safety and the efficacy of CAR-T cell therapy.嵌合抗原受体T细胞结构设计的研究进展.嵌合抗原受体（CAR）-T细胞疗法在复发难治性血液恶性肿瘤中的应用已经取得了令人鼓舞的临床疗效，但在靶向杀伤特异性、有效性以及安全性等方面均存在一定的挑战。近年来，国内外研究人员为解决CAR-T细胞疗法所存在的问题在CAR基因结构优化方面进行了深入的研究。本文主要阐述CAR基因中胞外结构域、跨膜区和胞内结构域的优化以及新型CAR基因设计，为进一步提高CAR-T细胞疗法的安全性和有效性提供新信息。.
Ectodomain
Cell therapy
Cite
Citations (0)
Cell therapy
CAR T-cell therapy
Cite
Citations (96)
Cytokine Release Syndrome
Cell therapy
Cancer Immunotherapy
Cite
Citations (0)
Chimeric antigen receptor modified T cell (CAR T) cytotherapy is a modified technology of T cell immunotherapy. It has achieved encouraging breakthroughs in the treatment of hematological malignancies. Recent studies had shown that CAR T cells can also be used in the treatment of solid tumors. However, it's indispensable to understand its bottlenecks, including regulating CAR T cell expansion, survival time, metastasis, and prognosis in vivo, to establish a feasible and effective CART-based solid tumor therapy model. Therefore, we summarized the advances, challenges and possible solutions for CAR T therapy to treat solid tumors, and then prospected in the future clinical treatment.嵌合抗原受体修饰T细胞(CAR T)技术是经过改造后的T细胞免疫治疗，在治疗血液系统恶性肿瘤中取得显著效果。近年来，CAR T细胞同样可应用于实体肿瘤的治疗。然而，如何有效地将CAR T细胞免疫疗法转化到实体肿瘤治疗中，需要认识其在实体肿瘤临床治疗中的瓶颈，包括调节CAR T细胞体内扩增、存活时间、转移以及在肿瘤组织内的转归等因素。文章阐述了近年来CAR T细胞治疗实体肿瘤的研究现状、CAR T细胞治疗过程中遇到的一些瓶颈以及可能的解决办法，并对未来CAR T细胞治疗实体肿瘤的发展趋势进行分析和展望。.
Solid tumor
Cell therapy
Cite
Citations (0)
Cite
Citations (1)
The clinical success stories of chimeric antigen receptor (CAR)-T cell therapy against B-cell malignancies have contributed to immunotherapy being at the forefront of cancer therapy today. Their success has fueled interest in improving CAR constructs, identifying additional antigens to target, and clinically evaluating them across a wide range of malignancies. However, along with the exciting potential of CAR-T therapy comes the real possibility of serious side effects. While the FDA has approved commercialized CAR-T cell therapy, challenges associated with manufacturing, costs, and related toxicities have resulted in increased attention being paid to implementing CAR technology in innate cytotoxic natural killer (NK) cells. Here, we review the current landscape of the CAR-NK field, from successful clinical implementation to outstanding challenges which remain to be addressed to deliver the full potential of this therapy to more patients.
Cell therapy
Cancer Therapy
Cancer Immunotherapy
CAR T-cell therapy
Cite
Citations (96)
Cell therapy
Cite
Citations (38)
Cytokine Release Syndrome
Cite
Citations (4)
Cytokine Release Syndrome
Suicide gene
Cell therapy
Cite
Citations (3)